Labiotech.eu

More News! 31 Jan 2019

Novozymes Signs Deal to Develop Biodegradable Plastics

The Danish enzyme manufacturer Novozymes has launched a joint development collaboration with the French biotech Carbios to commercialize biodegradable plastics. Under the agreement, Novozymes is to use its manufacturing muscle to scale up and produce Carbios’ plastic-degrading enzyme technology for Carbios’ subsidiary company Carbiolice. Carbiolice is to embed these enzymes into single-use plastics, such as […]

January 31, 2019 - 2 minutesmins - By Jonathan Smith

orphazyme niemann pick type c disease rare metabolic disease molecules

News and Trends 30 Jan 2019

Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial

A drug, developed by the Danish biotech Orphazyme for a rare metabolic disease, has shown promising results in a phase II/III trial, reducing the disease’s progression by 74%. The 50 patients recruited into the trial suffered from Niemann-Pick disease type C, a metabolic disease in which proteins crucial for storing fat molecules such as cholesterol […]

January 30, 2019 - 3 minutesmins - By Jonathan Smith

Expert Advice 30 Jan 2019

Life Science Email Marketing Best Practices on a Limited Budget

Email marketing is almost as old as the internet itself, and it’s just as relevant to modern businesses. To be in possession of someone’s email (especially when they want you to have it), means you have a direct line to their mind. Every economically active demographic uses email. Despite every kind of challenge […]

January 30, 2019 - 8 minutesmins - By James Mathison

destiny pharma mrsa antibiotic resistance

More News! 29 Jan 2019

Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I

An antibiotic nasal gel, developed by the UK company Destiny Pharma to treat drug-resistant bacterial infections, has shown no adverse effects in healthy volunteers in a phase I trial. Destiny’s antibiotic nasal gel is designed to prevent post-surgical infections of the bacterial species Staphylococcus aureus, which can come in the dangerous drug-resistant strain MRSA. “About […]

January 29, 2019 - 3 minutesmins - By Jonathan Smith

UK Policy Antimicrobial Resistance Biotech

News and Trends 28 Jan 2019

New UK Policy Benefits Biotechs Waging War on Superbugs

Among other measures, the new policy changes the way companies are reimbursed for antimicrobial drugs, which is expected to increase investment in biotech and the interest of big pharma in tackling antimicrobial resistance. Antimicrobial resistance is a huge problem. More and more pathogens are becoming resistant to antibiotics, as seen in the rising number of […]

January 28, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 28 Jan 2019

5 Real-Life Technologies Where Biotech Meets Science Fiction

From genetic engineering to synthetic food and immortality, biotech is getting surprisingly close to recreating science fiction in real life. Science fiction is always a step ahead of real-life science. The genre imagined space travel, wireless communication and virtual reality years before they became a reality. In fact, sci-fi has coined some scientific terms […]

January 28, 2019 - 6 minutesmins - By Clara Rodríguez Fernández

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […]

January 28, 2019 - 3 minutesmins - By Dani Bancroft

Philogen cancer immunotherapy antibody pharma t cell

News and Trends 25 Jan 2019

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies that are fused with proteins that modify the immune system to fight diseases such as cancer. For example, this treatment can bind to tumors and activate […]

January 25, 2019 - 2 minutesmins - By Jonathan Smith

Startup Scout 25 Jan 2019

This Biotech Makes Cosmetics out of Seaweed

Algaia is a French biotech based in Brittany, and for good reason. Here it harvests the blankets of Atlantic seaweed on the coast and extracts products for use in food, cosmetics and more. Mission: To maximize the number of useful products you can extract out of seaweed. Algaia uses seaweed as a source of useful […]

January 25, 2019 - 3 minutesmins - By Jonathan Smith

exxonMobil biofuel renewable energy group clariant

More News! 24 Jan 2019

ExxonMobil Recruits Swiss Company to Make Biofuels

The Swiss biofuels company Clariant is joining up with US companies ExxonMobil and the Renewable Energy Group to make biodiesel from agricultural waste. The new partnership hopes to combine technology from the Renewable Energy Group and Clariant to produce biodiesel — a biofuel that is a mix of ethanol and fat or cooking greases. Unlike […]

January 24, 2019 - 2 minutesmins - By Jonathan Smith

PharmaBiome microbiome ulcerative colitis

Interview 23 Jan 2019

Tackling the Complexity of the Gut Microbiome for Better Treatments

An imbalance in gut microbe species is linked with gastrointestinal disease. Philip talked with the CEO and co-founder of the Swiss startup PharmaBiome, Tomas de Wouters, about the complexity of rebalancing the gut microbiome in these conditions. The microbiome is a hugely complex ecosystem of microbes living all around the body. Different parts of the […]

January 23, 2019 - 5 minutesmins - By Jonathan Smith

huntingtons disease gene therapy uniqure2 1

News and Trends 23 Jan 2019

Update: The FDA Green-lights Clinical Trials for Huntington’s Disease Gene Therapy

Update (23/01/2019): The FDA has given uniQure regulatory clearance to begin a phase I/II trial of its gene therapy for Huntington’s disease. uniQure is planning to launch the trial in the US in late 2019. Published on 23/01/2018: The EMA has given uniQure’s gene therapy candidate for Huntington’s disease Orphan Medicinal Product Designation, which the […]

January 23, 2019 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novozymes Signs Deal to Develop Biodegradable Plastics

Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial

Life Science Email Marketing Best Practices on a Limited Budget

Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I

New UK Policy Benefits Biotechs Waging War on Superbugs

5 Real-Life Technologies Where Biotech Meets Science Fiction

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

This Biotech Makes Cosmetics out of Seaweed

ExxonMobil Recruits Swiss Company to Make Biofuels

Tackling the Complexity of the Gut Microbiome for Better Treatments

Update: The FDA Green-lights Clinical Trials for Huntington’s Disease Gene Therapy

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!